Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback